Collegium Pharmaceutical Inc (COLL)vsHaleon plc (HLN)
COLL
Collegium Pharmaceutical Inc
$29.47
+1.24%
HEALTHCARE · Cap: $1.15B
HLN
Haleon plc
$10.03
0.00%
HEALTHCARE · Cap: $43.07B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 1285% more annual revenue ($11.03B vs $796.33M). HLN leads profitability with a 15.1% profit margin vs 9.4%. COLL trades at a lower P/E of 17.2x. HLN earns a higher WallStSmart Score of 63/100 (C+).
COLL
Buy50
out of 100
Grade: C-
HLN
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.1%
Fair Value
$378.01
Current Price
$29.47
$348.54 discount
Intrinsic value data unavailable for HLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 27 in profit
Attractively priced relative to earnings
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Earnings declined 46.6%
Distress zone — elevated risk
Elevated debt levels
0.6% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on Return on Equity, P/E Ratio.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : COLL
The primary concerns for COLL are Market Cap, EPS Growth, Altman Z-Score. Debt-to-equity of 2.59 is elevated, increasing financial risk.
Bear Case : HLN
The primary concerns for HLN are Revenue Growth, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
COLL carries more volatility with a beta of 0.73 — expect wider price swings.
COLL is growing revenue faster at 8.9% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HLN scores higher overall (63/100 vs 50/100), backed by strong 15.1% margins. COLL offers better value entry with a 88.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?